Vaginal cytokines do not correlate with postmenopausal vulvovaginal symptoms

References

• Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7:310–17
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1–66
   PubMed Web of Science ®Google Scholar
• Donders GG, Bosmans E, Dekeersmaecker A, et al. Pathogenesis of abnormal vaginal bacterial flora. Am J Obstet Gynecol 2000;182:872–8
   PubMed Web of Science ®Google Scholar
• Fidel PL, Jr Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996;9:335–48
   PubMed Web of Science ®Google Scholar
• Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004;71:761–9
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat. Toxicol Pathol 2007;35:910–27
   PubMedGoogle Scholar
• Galen BT, Martin AP, Hazrati E, et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 2007;195:1332–9
   PubMed Web of Science ®Google Scholar
• Petricevic L, Unger FM, Viernstein H, Kiss H. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2008;141:54–7
   PubMed Web of Science ®Google Scholar
• Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999;42:93–106
   PubMed Web of Science ®Google Scholar
• Fichorova RN, Lai JJ, Schwartz JL, et al. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials. Cytokine 2011;55:134–40
   PubMed Web of Science ®Google Scholar
• Al-Harthi L, Wright DJ, Anderson D, et al. The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res 2000;20:719–24
   PubMedGoogle Scholar
• Macneill C, de Guzman G, Sousa GE, et al. Cyclic changes in the level of the innate immune molecule, surfactant protein-a, and cytokines in vaginal fluid. Am J Reprod Immunol 2012;68:244–50
   PubMed Web of Science ®Google Scholar
• Africander D, Louw R, Verhoog N, et al. Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception 2011;84:423–35
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco JA, Arici A. Chemokines and human reproduction. Fertil Steril 1999;71:983–93
   PubMed Web of Science ®Google Scholar
• Dahn A, Saunders S, Hammond JA, et al. Effect of bacterial vaginosis, lactobacillus and premarin estrogen replacement therapy on vaginal gene expression changes. Microbes Infect 2008;10:620–7
   PubMed Web of Science ®Google Scholar
• Stute P, Kollmann Z, Bersinger N, et al. Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation. Menopause 2014:840–5
   PubMedGoogle Scholar
• Heinemann LA, DoMinh T, Strelow F, et al. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes 2004;2:67
   PubMedGoogle Scholar
• Bachmann G. Vulvo-vaginal complaints. In: Lobo R, ed. Treatment of the postmenopausal woman. New York: Raven Press; 1994:137–42
   Google Scholar
• Da Silva JA. Sex hormones and glucocorticoids: interactions with the immune system. Ann N Y Acad Sci 1999;876:102–17; discussion 17–18
   PubMed Web of Science ®Google Scholar
• Yasui T, Maegawa M, Tomita J, et al. Changes in serum cytokine concentrations during the menopausal transition. Maturitas 2007;56:396–403
   PubMed Web of Science ®Google Scholar
• Cioffi M, Esposito K, Vietri MT, et al. Cytokine pattern in postmenopause. Maturitas 2002;41:187–92
   PubMed Web of Science ®Google Scholar
• Tani A, Yasui T, Matsui S, et al. Different circulating levels of monocyte chemoattractant protein-1 and interleukin-8 during the menopausal transition. Cytokine 2013;62:86–90
   PubMed Web of Science ®Google Scholar
• Deguchi K, Kamada M, Irahara M, et al. Postmenopausal changes in production of type 1 and type 2 cytokines and the effects of hormone replacement therapy. Menopause 2001;8:266–73
   PubMed Web of Science ®Google Scholar
• Herold BC, Keller MJ, Shi Q, et al. Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. J Acquir Immune Defic Syndr 2013;63:485–93
   PubMed Web of Science ®Google Scholar
• Anton G, Rid J, Mylonas I, et al. Evidence of a TH1-shift of local vaginal inflammatory response during bacterial vaginosis. Infection 2008;36:147–52
   PubMedGoogle Scholar
• Hedges SR, Barrientes F, Desmond RA, Schwebke JR. Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis 2006;193:556–62
   PubMed Web of Science ®Google Scholar
• Al-Harthi L, Kovacs A, Coombs RW, et al. A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS 2001;15:1535–43
   PubMed Web of Science ®Google Scholar
• Su HI, Schreiber CA, Fay C, et al. Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides. Contraception 2011;84:525–32
   PubMed Web of Science ®Google Scholar
• Anderson DJ, Williams DL, Ballagh SA, et al. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol 2009;61:121–9
   PubMed Web of Science ®Google Scholar
• Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007;21:467–76
   PubMed Web of Science ®Google Scholar
• Schwartz JL, Mauck C, Lai JJ, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 2006;74:133–40
   PubMedGoogle Scholar
• Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001;184:418–28
   PubMed Web of Science ®Google Scholar
• Belec L, Gherardi R, Payan C, et al. Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995;7:568–74
   PubMed Web of Science ®Google Scholar
• Tjiong MY, van der Vange N, ter Schegget JS, et al. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine 2001;14:357–60
   PubMed Web of Science ®Google Scholar
• Shrier LA, Bowman FP, Lin M, Crowley-Nowick PA. Mucosal immunity of the adolescent female genital tract. J Adolesc Health 2003;32:183–6
   PubMedGoogle Scholar
• Babula O, Lazdane G, Kroica J, et al. Frequency of interleukin-4 (IL-4) –589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005;40:1258–62
   PubMed Web of Science ®Google Scholar
• Sachdeva RK, Wanchu A, Bagga R, et al. Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women. J Interferon Cytokine Res 2010;30:299–310
   PubMedGoogle Scholar
• US Department of Health and Human Services. US Food and Drug Evaluation and Research. Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation. January 2003. Available at: http://www.fda.gov/cder/guidance/5412dft.doc
   Google Scholar
• Kyongo JK, Jespers V, Goovaerts O, et al. Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One 2012;7:e43951
   Google Scholar
• Mukura LR, Ghosh M, Fahey JV, et al. Genital tract viral load in HIV Type 1-positive women correlates with specific cytokine levels in cervical-vaginal secretions but is not a determinant of infectious virus or anti-HIV activity. AIDS Res Hum Retroviruses 2012;28:1533–9
   PubMedGoogle Scholar
• Fichorova RN, Richardson-Harman N, Alfano M, et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 2008;80:4741–51
   PubMed Web of Science ®Google Scholar
• Kamada M, Irahara M, Maegawa M, et al. Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol 2001;184:309–14
   PubMed Web of Science ®Google Scholar
• Berg G, Ekerfelt C, Hammar M,R, et al. Cytokine changes in postmenopausal women treated with estrogens: a placebo-controlled study. Am J Reprod Immunol 2002;48:63–9
   PubMed Web of Science ®Google Scholar